Details checkedClinical trial listing onlyHistorical/discontinuedCheckedregistry

Triamcinolone Levels in Cochlear Perilymph Study

Also known as: Triamcinolone Acetonide, Triamcinolone Levels in Cochlear Perilymph, NCT03248856

Investigator-led study

Primary source

Sponsor / Institution

Investigator-led study

Program Type

Therapeutic

Modality

Steroid/Anti-inflammatory

Stage

Phase 1

Status

Completed

Target Gene

—

Route / Mode

Intratympanic administration

Confidence

84%

Status Confidence

Status needs checking

Evidence Strength

Needs more support

Last Reviewed

2026-06-10

Geography

Austria

Population

cochlear-implant, pharmacokinetic

Trial IDs

Mechanism

Completed Phase 1 investigator-led pharmacokinetic study measuring cochlear perilymph triamcinolone levels after intratympanic triamcinolone acetonide before sampling.

Indications

Hearing Loss

Notes

Verified as a completed intratympanic triamcinolone pharmacokinetic/perilymph-level study. This is study-level pharmacology evidence rather than an active commercial hearing-loss product program.

Evidence & Sources

1 structured sources

clinicaltrials

Supports: canonicalName, aliases, company, allCompanies, isIndustrySponsored, programType, modality, mechanism...

IDs: NCT03248856

Open

Key Events

2017-10-02

Registry lists actual start of triamcinolone perilymph-level study

2021-05-31

Registry lists actual completion of triamcinolone perilymph-level study

Clinical Trials (1)